Open AccessRosuvastatin-induced rhabdomyolysis: A case report
Author(s) -
Ravindra Nikalji,
Suvadeep Sen
Publication year - 2021
Publication title -
indian journal of nephrology/indian journal of nephrology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 24
eISSN - 1998-3662
pISSN - 0971-4065
DOI - 10.4103/ijn.ijn_388_19
Subject(s) - rhabdomyolysis , medicine , rosuvastatin , acute kidney injury , statin , myopathy , pharmacovigilance , hyperkalemia , dialysis , intensive care medicine , adverse effect
Rosuvastatin is a recently approved statin and used widely across the globe for primary and secondary prevention of atherosclerotic cardiovascular heart disease. It has the highest lipid-lowering property among all statins and relatively well tolerated. Rhabdomyolysis is a rare but potentially serious adverse effect. The present report highlights the case of a patient admitted with proximal myopathy with severe rhabdomyolysis and acute kidney injury associated with life-threatening hyperkalemia. The symptoms appeared within 1 month of starting rosuvastatin. He required temporary dialysis to overcome the crisis. His myopathy and kidney injury were completely reversible after a few months of stopping the drug. In this report, we have also discussed the various risk factors for developing myopathy with statins and the importance of strict pharmacovigilance, and a greater caution among physicians while using this drug.